ULURU Inc. to Present Altrazeal Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
ADDISON, Texas, March 18, 2009 /PRNewswire-FirstCall/ -- ULURU Inc. announced that clinical evidence on the treatment of diabetic foot ulcers, and data on the use of its patented Nanoflex(TM) Technology for Therapeutic Delivery will be presented at the annual DFCon Global Meeting in Los Angeles, California March 19-21. The work will be presented on posters that will be on display during the meeting.
Clinical evidence will be presented on a poster titled, "Nanoparticulate Aggregate Wound Dressing in the Management of Soft Tissue Wounds". This research details the application of Altrazeal(TM) in the treatment of a patient following radical debridement of necrotizing fasciitis. Commenting on the work, DFCon organizer and one of the study's co-authors, Dr. David Armstrong, Professor of Surgery and Director, Southern Arizona Limb Salvage Alliance (SALSA) College of Medicine stated, "We have been provisionally impressed with this modality. We believe that marrying such technologies with an aggressive team effort might well prove helpful in reducing the unnecessarily high rate of amputations in the USA and worldwide."
Further clinical evidence for the use of Altrazeal(TM) in treating diabetic foot ulcers is detailed in a poster titled "Properties of a Novel Powder Wound Dressing and Clinical Experience in Diabetic Foot Ulcers." This work presents the use of Altrazeal(TM) Transforming Powder Dressing in the treatment of four separate ulcers in diabetic patients. The treatments were performed by Gregory Bohn, MD FACS, the Medical Director of Trinity Center for Wound Care and Hyperbaric Medicine in Bettendorf, IA., Sid Sharma, DPM FAPWCA, and Gianni Persich, DPM FAPWCA both at All Country Podiatry in NY. Four cases of ulcers present on heel, toe or ankle are shown and each was treated with Altrazeal(TM) following wound bed preparation. For all four patients, the time to healing was between one and four weeks and one patient's ulcer had been present in stasis for 24 weeks prior to Altrazeal(TM) treatment. Commenting on the results, Dr. Persich stated "Altrazeal(TM) represents a new generation of smart dressings which will greatly aid in treating these complex wounds."
A third poster titled "Nanoflex(TM) Technology Applied to the Development of Advanced Controlled Release Dressings" highlights the flexibility of ULURU's patented technology in the delivery of molecules both in the laboratory and in vivo animal models. Data is presented on the delivery of small molecule therapeutics and the delivery of the therapeutic protein, VEGF to a wound bed in a porcine model resulting in dramatic differences in the effects of controlled release on the healing endpoint. Dr. John St. John, Vice President of Research and Development for ULURU Inc. stated, "These results demonstrate evidence of the capability of our Nanoflex(TM) technology to allow the development of medical devices to target the specific phases of the wound healing cycle."
Abstracts for these posters are available on the DFCon website at http://www.dfcon.com/abstracts.html.
is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Nanoflex(TM) Aggregate technology. For further information about ULURU Inc., please visit our website at www.uluruinc.com.
Contact: Company Renaat Van den Hooff President & CEO Terry K. Wallberg Vice President & CFO (214) 905-5145
CONTACT: Company, Renaat Van den Hooff, President & CEO, or Terry K.Wallberg, Vice President & CFO, both at +1-214-905-5145, both of ULURU Inc.
Web site: http://www.uluruinc.com/
Ticker Symbol: (NYSE:ULU)
Terms and conditions of use apply
Copyright © 2009 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: March 2009